Cipla rating: Neutral — Opex fall led to strong beat on earnings in Q1

By: |
August 11, 2020 5:00 AM

Ebitda margin registered a high; FY21/22e EPS up by 19/14%; ‘Neutral’ retained with revised TP of Rs 790.

An employee of Cipla LTD works in the steroid manufacturing area of the Kurkumb, India, (Image: Bloomberg)

Cipla’s sales for the quarter were largely in line with our estimates. However, it delivered a strong beat on earnings owing to significant reduction in opex. COVID-19-led disruption has enthused the company to re-imagine the business, to sustain cost saving and enhance resource productivity.

We raise our EPS estimates by 19%/14% for FY21/FY22 to factor in above-market growth in Trade Generics (Gx), ramp-up in Albuterol Sulfate sales, and cost saving benefits. We raise our price target to Rs 790 as we roll out our price target on a 22x 12M forward basis. Maintain Neutral, as the valuation factors in potential upside in earnings over the medium term.

Highest Ebitda margin in the past 20 quarters: Cipla’s Q1FY21 revenues were up 9% y-o-y at Rs 43.5 bn. Domestic sales grew to Rs 16.1 bn (+16% y-o-y). Branded Formulations sales in India were up by 9% on a y-o-y basis and Trade Generics by a strong 46% y-o-y. SAGA (South Africa Global Access) revenue grew 10% y-o-y to Rs 7.6 bn. Emerging Markets (EM) sales rose 64% y-o-y to Rs 4.6 bn. EU sales grew 19% y-o-y to Rs 2.4 bn. North America sales were down 9% y-o-y to Rs 10 bn ($135 m) on the high base of the past year.

Gross margin decreased by ~630bp y-o-y to 63.4%, attributed to a change in the product mix. However, Ebitda margin expanded ~140bp y-o-y to 24.1% on lower other expenses/employee cost (-670bp/-120bp y-o-y as % of sales). Ebitda improved by ~16% y-o-y to Rs10.5 bn. Adj. PAT grew at a higher rate of 21% y-o-y to Rs 5.8 bn on a lower tax rate.

Highlights from commentary: Cipla expects Rs 4-5 bn savings in opex on an annual basis in FY21, led by lower travel/conference expenses due to COVID-19. Cipla now has 65% of Proventil’s market share. It has 6%/8% market share of Albuterol/Albuterol Generics + AG weekly Rx. There are opportunities to take market share in the generic Albuterol market. Pricing has reduced by 25–30% from Jan’20 levels.

Valuation and view

We expect a 29% earnings CAGR, led by niche launches in US Generics, coupled with a ramp-up in Albuterol Sulfate and improved growth through renewed strategy in Domestic Formulations (DF). We value Cipla at 22x 12M forward earnings to arrive at TP of Rs 790. Maintain Neutral rating.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Tata Steel share price hits new 52-week high yet again post Q4 results; stock surges 85% so far in 2021
2Foreign investors turn net sellers after 6 months of inflows; trim stake in these sectors in April
3Nirma Group cement company Nuvoco Vistas files IPO papers with SEBI; plans to launch Rs 5,000 cr public issue